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Objective: To examine ovarian cancer incidence and mortal­
ity in the Netherlands, and to relate trends in mortality to 
changes in parity and use of oral contraceptives.
Methods: Age-standardized and age-specific incidence and 
mortality rates are presented using incidence data from the 
Netherlands Cancer Registry, 1989-1991, and mortality data 
from the Netherlands Central Bureau of Statistics, 1954- 
1993.
Results: In  the period 1989-1991, age-standardized inci­
dence of ovarian cancer was 14.9 per 105 woman-years. The 
majority (89%) of these tumors had an epithelial origin. 
Two-thirds of all newly diagnosed ovarian cancers already 
showed extension to the pelvis or beyond at diagnosis. From 
the period 1954-1958 to 1969-1973, age-standardized mortal­
ity rates increased from 10.6 to 13.1 per 105 woman-years. 
Thereafter, a decline was noted to 11.4 per 105 woman-years 
in the period 1989 “1993. Age-specific mortality rates showed 
a pattern of rising mortality in the elderly, whereas mortality 
in the younger age categories was declining. The number of 
live births has declined gradually, and oral contraceptive use 
has increased.
Conclusion'. Incidence of ovarian cancer is high in the 
Netherlands, but comparable to other countries in north­
western Europe and North America. Mortality rates are 
rising in the elderly and declining in the young. Further 
research is needed concerning the effects of oral contracep­
tives, fertility drugs, and hormone replacement therapy on 
the incidence and mortality of ovarian cancer. (Obstet Gy­
necol 1996;88:387-93)
Ovarian cancer is one of the most frequent malignancies 
in women and shows a wide geographic variation in 
incidence. Highest risks are observed among the more 
affluent populations in northwestern Europe and North
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America, with a 1-2% cumulative risk of being diag­
nosed with ovarian cancer before the age of 75.1,2 The 
majority of the ovarian cancers remain unnoticed until 
disease has spread beyond the ovary. Survival rates 
have increased since the introduction of more aggres­
sive treatment modalities in the late 1970s (extensive 
surgery followed by platinum-based chemotherapy 
regimens), but are still extremely poor. Reported stage- 
specific 5-year survival rates range from approximately 
80% for localized disease to less than 10 % in case of 
distant métastasés,2"7 At present, ovarian cancer re­
mains the most lethal gynecologic malignancy in the 
western world.7
Extensive research has been done in the etiology of 
ovarian cancer, but so far the pathogenesis is only 
partially understood.8 The key findings in this field are 
the identification of genetic factors related to ovarian 
cancer and the important role of the hormonal system in 
the etiologic pathway.5,8"13 Fathaila (Incessant ovula­
tion: A factor in ovarian neoplasia [letter]. Lancet 1971; 
ii:163) suggested that the disruption of the ovarian 
epithelium at ovulation may represent the key step 
leading to malignant transformation. Consequently, 
fewer ovulations during a woman's lifetime might lead 
to a lower risk of ovarian malignancy. The protective 
effect of increased painty, breast feeding, and use of oral 
contraceptives (OC) found in several studies is consis­
tent with this hypothesis of “incessant ovulation/78"13 
Oral contraceptives were introduced in the 1960s and 
gained widespread use thereafter. Consequently, the 
potential protective effect of OCs could result in a 
decline in the occurrence of ovarian cancer. Evidence of 
such a decreasing trend in incidence and/or mortality is 
already found in several countries around the 
world.1,2,14-23 However, large geographic variations ex­
ist, and the major decrease is still to come because most 
women who used OCs are only now reaching high-risk
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Figure 1. Age-specific ovarian can­
cer incidence in the Netherlands, 
1989-1991. Cum. = cumulative.
5-Year age category
ages for developing ovarian cancer.24 The aim of this 
study was to investigate the incidence and mortality of 
ovarian cancer in the Netherlands, Because national 
incidence data were available only recently, the empha­
sis will be on the analysis of mortality data.
Materials and Methods
Numbers of newly diagnosed ovarian cancers for the 
period 1989-1991 were derived from the Netherlands
Cancer Registry.25 For ovarian cancer, we used Interna­
tional Classification of Diseases (ICD) for Oncology 
code 183.0.26 Data regarding morphology and lateral­
ization were derived directly from the registry records. 
The Netherlands Cancer Registry records International 
Federation of Gynecology and Obstetrics (FIGO) stage 
from 1992 onward. Therefore, the FIGO stage of all 
diagnosed cases had to be assigned retrospectively by 
using the clinical and pathologic tumor node metastasis 
classification.27
Data regarding the number of women with ovarian 
cancer as the underlying cause of death as well as the 
age- and calendar year-specific numbers of Dutch fe­
males were abstracted from publications of the Nether­
lands Central Bureau of Statistics for the years 1954- 
.1993.28/29 During this period, death from ovarian cancer 
was coded as 175.3-175.5 according to the ICD-6 (1954- 
1957), 175.0 according to I CD-7 (1958-1968), and there­
after as 183.0 according to ICD-8 and ICD-9.
Age-specific incidence rates are presented for the
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years 1989-1991 combined. All rates are expressed in 
10s woman-years. In addition to the crude incidence 
rate, the age-standardized incidence rate using the 
European Standard Population30 and the cumulative 
risk of ovarian cancer before the age of 75 are presented. 
Age-specific mortality rates are presented by 5-year 
calendar periods (1954-1958 to 1989-1993). Age- 
standardized rates (all ages) are presented for the same 
periods.
Results
Since the start of the Netherlands Cancer Registry in 
1989, 3622 new cases of ovarian cancer have been 
registered in the Netherlands in the period 1989-1991. 
Age-specific incidence rates gradually increased to 57.3 
per 105 woman-years for the 75-79 age category (Figure
ET
1). The age-standardized incidence rate is 14.9 per 10 
woman-years. Of all ovarian cancers diagnosed in the 
period 1989-1991, 89% had an epithelial origin (adeno, 
endometrioid, and clear cell carcinomas), with the ma­
jority being serous and mucinous cystic adenocarcino­
mas (Table 1). Germ cell tumors were especially fre­
quent at younger ages; 66% (43 of 65) occurred at ages 
under 40. Moreover, 30% (30 of 99) of all ovarian 
cancers of known morphology that occurred before the 
age of 30 were of germ cell origin. In two of every three 
cases of ovarian cancer diagnosed in this period, the 
tumor showed extension to the pelvis (FIGO stage II) or 
beyond (FIGO stage III or IV). In 239 cases (6.6%), the
Obstetrics & Gynecology
T able 1. D istribu tion  of M orphology, Stage, and
Lateralization of O varian Cancer in the 
N etherlands, 1989-1991
Cases (//)
Morphology 
Serous cystic adenocarcinoma 
Mucinous cystic adenocarcinoma 
Other adenocarcinoma 
Endometrioid carcinoma 
Clear cell carcinoma 
Sex cord stromal tumor 
Germ cell tumor 
Other specified morphology 
Unspecified morphology 
Tumors not microscopically verified 
FIGO stage 
Tumor limited to one or both ovaries
I*
la
lb
Ic
Pelvic extension
II*
Ha
lib
lie
Microscopically confirmed peritoneal 
metastasis outside the pelvis 
and /or regional lymph node 
metastasis
nr
Ilia
Illb
IIIc
Distant metastasis1 
IV
Unknown*
Lateralization
Bilateral
Left
Right
Unknown*
Total
1090
498
1193
305
139
50
65
136
71
75
86
75
55
328
9
51
150
124
334
174
362
630
605
239
1177
893
999
553
3622
(%)
(30.1%)
(13.7%)
(32.9%)
(8.4%)
(3.8%)
(1.4%)
(1 .8%)
(3.8%)
(2.0%)
(2.1%)
(2.4%)
(13.1%)
(1.5%)
(9.1%)
(0.3%)
(1.4%)
(4.1%)
(3.4%)
(9.2%)
(4.8%)
(10.0%)
(17,4%)
(16.7%)
(6.6%)
(32.5%)
(24.6%)
(27.6%)
(15.3%)
(100.0%)
F1CO = International Federation of Gynecology and Obstetrics.
* Not enough information available to allot cases to subcategories.
+ Liver metastasis must be of parenchymal tissue to allot a case to 
FIGO stage IV. Pleural effusion must have positive cytology for FIGO 
stage IV,
necessary requirements for FIGO staging were not met. 
Almost one-third of all patients (1177 cases) had bilat­
eral disease. The right-to-left ratio was 1.12, indicating 
that right-sided tumors occurred slightly more often. In 
15.3% of all cases, no lateralization was specified.
increased gradually until 1969-1973, but we found a 
decline to 11.4 per 10* woman-years in 1989-1993 
thereafter (Table 2). When age-specific mortality rates 
are considered, a more diverse pattern in mortality rates 
can be observed (Table 2, Figure 2). Whereas the 
younger age groups showed relatively stable or even 
slightly declining mortality rates after the period 1969- 
1973, the older age groups showed an increasing trend 
in mortality. This is illustrated in Figure 2 (for clarity, 
age-specific mortality rates are presented by 10 -year age 
groups).
Discussion
The age-standardized incidence of ovarian cancer in the 
Netherlands is in the same order of magnitude as 
described for Sweden, Denmark, Germany, and Cana- 
da .14'16/18,19 The distribution of morphology, FIGO 
stage, and lateralization of all ovarian cancer cases in 
the Netherlands is also comparable to those reported in 
other studies.21,31 The slightly higher occurrence of 
ovarian cancer in the right ovary is probably due to 
chance because it was not found in a much larger study 
of unilateral ovarian cancers in the United States.31 
Age-specific rates are climbing with age. Several studies 
have described a pattern of declining incidence rates 
over time in younger ages, whereas an increase in 
incidence is described in older ages.18“21,21 Because the 
Netherlands Cancer Registry has been operational only 
since 1989, it was not possible to investigate the trend in 
incidence rates in our data. Instead, we investigated 
whether such a trend could be observed in mortality 
data available for the Netherlands over a much longer 
period. Ovarian cancer mortality in the Netherlands 
was relatively stable. However, age-specific mortality 
rates are rising in the older age-groups and are declin­
ing in the young. Several other studies, dealing with 
data from other countries, described a similar pattern in 
age-specific mortality over time,1,2,15"17,19"20 and many 
factors have been put forward to explain the observed 
changes.
Ewertz and Kjaer16 suggested that changes in parity 
between different birth cohorts of women could explain 
some of the observed variation in Danish ovarian 
cancer mortality rates. Recently, Dos Santos Silva and 
Swerdlow23 confirmed this hypothesis in their study of 
trends in incidence and mortality from breast, ovarian,
In 1954, ovarian cancer was the underlying cause of and endometrial cancers in England and Wales. In their 
death of 443 Dutch women. This number has steadily study, the marked decrease in family size was paral­
leled by an increase in the risk of ovarian cancer for 
successive birth cohorts born before 1920. In the Neth-
increased, reaching 1029 in 1993. However, after adjust­
ment for population growth and aging of the Dutch
female population, age-standardized mortality rates are erlands a similar pattern has been observed.32 34 The 
fairly stable. Age-standardized ovarian cancer mortality number of live births in the Netherlands has gradually
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Table 2. Age-Specific and Age-Standardized (European Population) O varian Cancer M ortality Rates (per 10? W oman-Years)
in the Netherlands, 1954-1993
Period of mortality
1954-1958 1959-1963 1964-1968 1969-1973 1974-1978 1979-1983 1984-1988 1989-1993
Age (y)
40-44 8.6 7.6 8.0 8.8 7.4 5.6 5.1 4.3
45-49 14.3 13.9 14.5 16.7 15.9 10.8 9.4 8.9
50-54 19.4 20.5 21.2 25.0 22.3 19.2 17.1 15.7
55-59 27.6 26.4 26.1 30.0 31.6 26.9 23.1 24.9
60-64 29.9 u3 3 . 0 34.5 35.1 36.7 34.9 34.9 33.7
65-69 31.4 36.8 40.1 44.1 40.4 39.0 44.7 44.8
70-74 38.1 41.3 43.7 51.3 51.0 46.9 50.5 55.0
75-79 40.0 37.5 50.5 57.4 61.7 62.1 63.2 60.7
80-84 38.2 41.2 51.4 54.4 56.9 56.0 67.9 65.6
sr85 38.9 35.2 52.9 47.6 55.9 55.6 66.2 68.4
Age-standardized rate
0-85 10.6 11.0 11.8 13.1 12.8 11.5 11.5 11.4
decreased since the beginning of this century (Figure 3). 
There was a temporary increase just after World War II, 
but the number of live births has decreased further and 
stabilized in recent years. Therefore, the increase in 
ovarian cancer mortality in the oldest age groups (bom 
around the turn of the century) may in part be attrib­
uted to their declining parity. This decrease in the 
number of live births is accompanied by an increase in 
the number of nulliparous women in the period 1945- 
1970.3° It is not clear how this lower parity and higher 
number of nulliparous women in the Dutch population 
will affect the ovarian cancer risk of younger birth 
cohorts. Moreover, one should be aware of the so-called
"ecologic fallacy/7 which implies that caution should be 
exercised when inferences are made from observed 
trends in population statistics because the apparent 
relationship may not hold on an individual level.
Dos Santos Silva and Swerdlow23 also found an 
inverse relationship between the number of women 
using OCs and the risk of ovarian cancer. This relation­
ship had already been observed earlier by Villard- 
Mackintosh et a l2G In the Netherlands, OCs were mar­
keted at the end of 1961 and gained widespread use 
(Figure 4). Apart from a slight decline in the number of 
women using OCs in the period 1977-1980 due to 
negative reports on the increased risk of cardiovascular
Mortality rate (per 100,000 woman-years)
Figure 2. Age-specific ovarian can­
cer mortality in the Netherlands,
1954-1993.
^  r
Period
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Number of live births (per 1,000 women)
Figure 3. Number of live births per 
1000 women aged 15-44 years in 
the Netherlands, 1900-1993,
Y ear
disease among women using OCs in that period, the 
percentage of women age 10-54 using OCs increased to 
32% in 1993. The dip in 1991 was caused by a lack of
been a trend to younger starting ages and prolonged 
use at older ages.34'36 These developments may have 
contributed to the stabilization and the onset of the
information on the quantity of parallel imported OCs in decrease in ovarian cancer mortality in the younger age 
that year and thus can be considered a registration groups in the Netherlands. If this is true, then the 
anomaly due to underreporting. There appears to have decreasing trend might continue when more birth co-
Use of oral contraceptives (%}
Figure 4. Percentage of women 
aged 10-54 years using oral contra­
ceptives in the Netherlands, 1967- 
1993. (Source: institute for Medical 
Statistics, the Netherlands.)
Year
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the blood gonadotropin levels, which might decrease 
the risk of ovarian cancer, according to the gonado­
tropin hypothesis put forward by StadeL41 Therefore, 
definitive conclusions about the effect on ovarian cancer 
risk of hormone replacement therapy cannot be drawn.
Whittemore et al9"11 suggested ovarian stimulation 
for in vitro fertilization could increase the risk of 
ovarian cancer. Recently, Venn et al42 reported an 
increase in ovarian cancer risk after ovarian stimulation 
for in vitro fertilization in a cohort of 10,358 Australian 
women. Although the number of cases in this large 
study was very small (n = 6), which limits the conclu­
sions that can be drawn, this finding supports the 
hypothesis of Whittemore et al. However, it is doubtful 
whether IVF has a large impact on population incidence 
and mortality even if the hypothesis is true. Further 
research into this matter is indicated.
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